uniQure (QURE)
(Delayed Data from NSDQ)
$4.69 USD
+0.01 (0.21%)
Updated May 3, 2024 04:00 PM ET
After-Market: $4.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
QURE 4.69 +0.01(0.21%)
Will QURE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for QURE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QURE
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Pfizer's (PFE) Hemophilia Candidate BLA Gets FDA Acceptance
QURE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?
Other News for QURE
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), uniQure (QURE) and eFFECTOR Therapeutics (EFTR)
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Kyowa Kirin’s rare disease therapy becomes world’s most expensive drug